Terms: = Skin cancer AND PRCC, Q92733, TPRC, RCCP1, MGC4723, MGC17178, ENSG00000143294, 5546 AND Treatment
3 results:
1. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
2. A construction and comprehensive analysis of ceRNA networks and infiltrating immune cells in papillary renal cell carcinoma.
Fan Y; Dai F; Yuan M; Wang F; Wu N; Xu M; Bai Y; Liu Y
Cancer Med; 2021 Nov; 10(22):8192-8209. PubMed ID: 34598322
[TBL] [Abstract] [Full Text] [Related]
3. CD98hc (SLC3A2), a novel marker in renal cell cancer.
Prager GW; Poettler M; Schmidinger M; Mazal PR; Susani M; Zielinski CC; Haitel A
Eur J Clin Invest; 2009 Apr; 39(4):304-10. PubMed ID: 19292886
[TBL] [Abstract] [Full Text] [Related]
